Class 530/387.3 - Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)

Subclass of Class 530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Definition: Subject matter involving an antibody or antibody fragment
No. of patents: 2060
Last issue date: 05/22/2012

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8183348	Non-invasive marker for liver function and disease A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver funct...	05/22/2012
8183347	Anti-TAT226 antibodies and immunoconjugates Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided. ...	05/22/2012
8183349	Markers of XMRV infection and uses thereof The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an ...	05/22/2012
8173779	Neutralizing human anti-IGFR antibody The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing th...	05/08/2012
8168758	Anti-MN antibodies and methods of using same The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder. ...	05/01/2012
8168759	Compositions monovalent for CD28 binding and methods of use Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically bind...	05/01/2012
8158758	Compositions and methods for treating and diagnosing cancer The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an inter...	04/17/2012
8158759	Compositions and methods relating to glucagon receptor antibodies The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodi...	04/17/2012
8158757	Compositions and methods for treating and diagnosing cancer The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an inter...	04/17/2012
8153765	Anti-CD38 antibodies for the treatment of cancer Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-me...	04/10/2012
8148496	Multivalent antibody constructs The present invention relates to a multivalent Fv antibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fv	04/03/2012
8148497	Binding molecules capable of neutralizing rabies virus and uses thereof The invention provides binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. The invention further provides nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods...	04/03/2012
8148498	DKK-1 antibodies The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1. ...	04/03/2012
8138314	Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and JαQ+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.	03/20/2012
8138315	Anti-alpha V immunoliposome compositions, methods and uses An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor compri...	03/20/2012
8133978	Humanised anti-interleukin-18 antibody The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potent...	03/13/2012
8133979	Antibodies against human angiopoietin 2 The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. ...	03/13/2012
8129504	Oral delivery of modified transferrin fusion proteins Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin mo...	03/06/2012
8124740	Anti- α5 β1 antibodies and uses thereof The present invention provides new anti-α5β1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies. ...	02/28/2012
8114967	Constructs and libraries comprising antibody surrogate light chain sequences The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chai...	02/14/2012
8106162	Artificial antibody polypeptides A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kit...	01/31/2012
8101722	Less immunogenic binding molecules The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino a...	01/24/2012
8101723	Monoclonal antibodies to fibroblast growth factor receptor 2 The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. ...	01/24/2012
8093360	Antibodies that bind exotoxin, formulations thereof, and methods of use The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically. ...	01/10/2012
8084584	Methods for stabilizing proteins The present inventors revealed that deamidation of an antibody can be suppressed without influencing its activity by substituting a glycine that is located adjacent to an asparagine with another amino acid. ...	12/27/2011
8080637	Therapeutic method of treating brain trauma in rodents with VCP The invention provides a method to treat a complication of neuronal injury in a mammal by inhibiting the complement cascade. ...	12/20/2011
8076459	Multispecfic deimmunized CD3-binders The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct i...	12/13/2011
8071731	Humanised anti-MAG antibody or functional fragment thereof The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ...	12/06/2011
8067546	Humanized anti-CD70 binding agents and uses thereof Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragmen...	11/29/2011
8067548	Fusion proteins having mutated immunoglobulin hinge region A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to t...	11/29/2011
8067549	Humanized antibodies and compositions for binding sphingosine-1-phosphate The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragment...	11/29/2011
8067547	Stable and soluble antibodies inhibiting TNFα The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, ...	11/29/2011
8058402	Antagonistic human LIGHT-specific human monoclonal antibodies Provided herein are antibodies, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. ...	11/15/2011
8053562	Modified antibody fragments The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) a...	11/08/2011
8039594	Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptos...	10/18/2011
8034903	Degraded TPO agonist antibody The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified an...	10/11/2011
8034905	Anti-VEGF antibody compositions and methods Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The pres...	10/11/2011
8034904	Anti-IGF-I receptor antibody Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-...	10/11/2011
8030454	Anti-hedgehog antibodies The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer. ...	10/04/2011
8026343	Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides ...	09/27/2011

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Did You Know...

PatentStorm News

Class 530/387.3 - Chimeric, mutated, or recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobulin fusion protein, etc.)